Relative frequency of drug-induced sleep disorders for 32 antidepressants in a large set of Internet user reviews.
Johan Natter, Taïoh Yokoyama, Bruno Michel
Sleep December 1, 2021 DOI: 10.1093/sleep/zsab174 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study using web-based drug review data (pharmacovigilance analysis) Peer reviewed |
|---|---|
| Sample size | 77,391 |
| Population | Patient comments about 32 antidepressant drugs posted on drug review websites |
| Measures | proportional reporting ratio (PRR), sentiment analysis |
| Keywords | Humans Antidepressive agents Reproducibility of results Internet Sleep wake disorders Mirtazapine Data mining Antidepressant Vilazodone Drug-induced sleep disorders |
| Key findings | Amitriptyline, doxepin, fluvoxamine, mirtazapine, nortriptyline, trazodone, venlafaxine, and vilazodone were associated with a greater frequency of antidepressant drug-induced sleep disorders than other antidepressants. Vilazodone was linked to higher probability of 5 of 6 studied sleep disorders (PRR 3.3 to 19.3) and mirtazapine to 4 (PRR 2.4 to 6.4), while bupropion and citalopram were associated with lower probabilities for 5 disorders (PRR 0.2 to 0.7). |
Abstract
Study
Objectives: It is known that antidepressant drugs can induce sleep disorders in patients, but little data exist about high or low-risk molecules. The aim was to study the frequency of antidepressant drug-induced sleep disorders (DISD) by molecule.
Methods: 77,391 patient comments for 32 antidepressant drugs were collected from drug review websites and screened for DISD. Association between drugs and nightmare disorder, restless legs syndrome, sleep paralysis, sleep terrors, sleep-related hallucinations, or sleep walking was expressed as relative proportion [proportional reporting ratio (PRR)]. A detailed analysis of the content of the dreams was also carried out.
Results: Amitriptyline, doxepin, fluvoxamine, mirtazapine, nortriptyline, trazodone, venlafaxine, and vilazodone were associated with a greater frequency of DISD compared to other antidepressants. Vilazodone heavily increased the probability of developing 5 of the 6 studied DISD (PRR 3.3 to 19.3) and mirtazapine increased the probability of developing 4 DISD (PRR 2.4 to 6.4). Bupropion and citalopram were associated with lower probabilities for 5 DISD (PRR 0.2 to 0.7). Sentiment analysis showed that patients described disturbing dreams for vilazodone or mirtazapine and strange but less negative dreams for bupropion, citalopram, or duloxetine.
Conclusions: Relative frequencies of sleep disorders were obtained for a vast panel of antidepressant drugs through an original analysis of user's drug reviews on drug rating websites. Our results could guide clinicians in the appropriate choice of antidepressant drugs for high DISD-risk patients in need of such treatment. These results may however be cautiously taken, considering the uncertain reliability and generalizability of web-based data.
Citations in the library
Cites 4
- Acute Psychosis Associated with Dissociated Sleep‐Wakefulness State After Mirtazapine Treatment Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy March 24, 2010
- Parasomnias: A Comprehensive Review. Cureus December 31, 2018
- Psychiatric Illness and Parasomnias: a Systematic Review. Current Psychiatry Reports July 2017
- Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Research December 27, 2000